


## Supplementary Material



**Figure S1.** C-terminal RAD51-binding domain (CTRBD) also confers resistance to X-ray irradiation and mitomycin C (MMC) treatment in HepG2 cells. **(A)** Expression of exogenous FLAG-HA-fused BRCA2 CTRBD (3260–3331 aa) and its mutants (S3291E and P3292L) was evaluated by western blotting, using an anti-FLAG antibody. Asterisks indicate nonspecific bands. **(B)** A clonogenic survival assay of FLAG-HA-fused BRCA2 CTRBD-expressing cells treated with X-ray irradiation is shown. Results are presented as the mean at each X-ray or MMC dose, and the error bars indicate the standard deviation ( $n = 3$ ). Significance was examined by F-test, followed by Student's  $t$ -test with Holm's correction. Asterisks indicate significant differences between empty vector-transduced HeLa cells and FLAG-HA-fused wild-type or P3292L-mutated BRCA2 CTRBD-expressing cells (\*:  $p < 0.05$ ).